Armata Pharmaceuticals (ARMP) News Today $7.60 -0.45 (-5.59%) Closing price 05/18/2026 04:10 PM EasternExtended Trading$7.75 +0.15 (+1.97%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock ARMP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period HC Wainwright Estimates Armata Pharmaceuticals Q2 EarningsMay 18 at 1:10 AM | americanbankingnews.comArmata Secures New Loan Amid Wider Quarterly LossMay 16 at 4:41 AM | theglobeandmail.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateMay 14, 2026 | finanznachrichten.deArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comArmata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on MondayMay 10, 2026 | marketbeat.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02May 7, 2026 | finanznachrichten.deArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02May 7, 2026 | prnewswire.comArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"May 4, 2026 | prnewswire.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 18.0% in AprilApril 30, 2026 | marketbeat.comArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.April 27, 2026 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Sees Large Volume Increase - Here's WhyApril 22, 2026 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 13.9% - Here's What HappenedApril 21, 2026 | marketbeat.comArmata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85April 16, 2026 | msn.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deArmata Pharmaceuticals stock edges down on fourth quarter earnings missMarch 26, 2026 | in.investing.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsMarch 25, 2026 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdateMarch 19, 2026 | finanznachrichten.deArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdateMarch 19, 2026 | prnewswire.comH.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA NodMarch 3, 2026 | finance.yahoo.comH.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA NodMarch 2, 2026 | insidermonkey.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02February 23, 2026 | finanznachrichten.deArmata Pharmaceuticals stock gains on FDA designationFebruary 23, 2026 | in.investing.comArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02February 23, 2026 | prnewswire.comArmata Pharmaceuticals (ARMP) price target increased by 33.33% to 12.24January 16, 2026 | msn.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated ...January 13, 2026 | finanznachrichten.deArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureusJanuary 13, 2026 | prnewswire.comJones Trading initiates coverage of Armata Pharmaceuticals (ARMP) with buy recommendationJanuary 6, 2026 | msn.comArmata Pharmaceuticals initiated with a Buy at JonesResearchJanuary 5, 2026 | msn.comArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am ESTNovember 18, 2025 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate UpdateNovember 14, 2025 | finanznachrichten.deArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate UpdateNovember 12, 2025 | prnewswire.comArmata announces comissioning of cGMP manufacturing facility in Los AngelesNovember 11, 2025 | msn.comArmata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, CaliforniaNovember 10, 2025 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in ...October 22, 2025 | finanznachrichten.deArmata Pharmaceuticals up 19% after reporting results of diSArm studyOctober 22, 2025 | msn.comArmata stock soars after positive Phase 2a bacteriophage trial resultsOctober 22, 2025 | za.investing.comArmata surges on mid-stage trial data for antibacterial agentOctober 22, 2025 | msn.comArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™October 22, 2025 | prnewswire.comArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™October 14, 2025 | prnewswire.comArmata Pharmaceuticals announces publication on phage Pa223September 8, 2025 | msn.comArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular BiologySeptember 8, 2025 | prnewswire.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comArmata Pharmaceuticals files $100M mixed securities shelfAugust 14, 2025 | msn.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deArmata Pharmaceuticals Secures $15M Loan for DevelopmentAugust 12, 2025 | msn.comArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 12, 2025 | prnewswire.comArmata Pharmaceuticals Inc.July 3, 2025 | barrons.comArmata Pharmaceuticals Insider Trading Activity | AMEX:ARMP | BenzingaMay 20, 2025 | benzinga.comArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus BacteremiaMay 19, 2025 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.de Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARMP Media Mentions By Week ARMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARMP News Sentiment▼0.260.59▲Average Medical News Sentiment ARMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARMP Articles This Week▼101▲ARMP Articles Average Week Get the Latest News and Ratings for ARMP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Armata Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Olema Pharmaceuticals News Today Jade Biosciences News Today Septerna News Today Corvus Pharmaceuticals News Today Collegium Pharmaceutical News Today Harrow News Today Maravai LifeSciences News Today DBV Technologies News Today Xeris Biopharma News Today Savara News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ARMP) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
